Conference Details - Overview
Continuing Education Information
Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource designates this educational activity for a maximum of 29 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA category 1 CME credit for the PRA from organizations accredited by the ACCME.
14th Annual International Congress on Hematologic Malignancies
The Fairmont Château Whistler
Whistler
March 17-21, 2010
Conference Overview
The 14th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myelomas provides a unique opportunity for physicians to learn from and to interact with international leaders in the field of hematologic malignancies in order to increase knowledge, apply new data to practice, and ultimately improve patient outcomes. This international CME-designated congress offers physicians the opportunity to learn about the latest developments in the treatment of hematologic malignancies, including findings presented at recent major oncology conferences, updates on the landscape for new drug indications and new agents, and ongoing clinical trials expected to impact practice in the near future. The instructional format of the congress is varied and includes didactic lectures, panel discussions, debates, and case-based presentations in order to accommodate the different learning styles of the participants. The congress is highly interactive, providing multiple opportunities for faculty-participant interaction. The multiple instructional formats used will enhance the learning experience and foster the integration of evidence-based patient care into everyday community practice.
This educational program is directed toward medical oncologists and hematologists interested in the treatment of patients with hematologic malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies are also invited to attend. At the conclusion of this congress, you should be able to:- Describe the biology of various hematologic malignancies that provides rationales for choosing treatment strategies
- Outline current treatment and monitoring strategies for patients with newly diagnosed leukemia, lymphoma, and myeloma
- Integrate new approaches into the frontline management of hematologic malignancies
- Discuss standard treatment options for patients with relapsed/refractory leukemia, lymphoma, and myeloma
- Assess the safety and efficacy of recent clinical advances in the management of patients with relapsed/refractory leukemia, lymphoma, and myeloma
- Evaluate emerging novel agents for the treatment of patients with leukemia, lymphoma, and myeloma
Educational Grants
An educational grant for this activity was provided by:
- Genentech BioOncology/
Biogen Idec - Cephalon Oncology
- Allos Therapeutics
- Bristol-Myers Squibb
- Eisai, Inc.
- Merck Oncology
- Novartis Oncology
- Lilly USA, LLC